Newly Launched AMD Integrative Biology Initiative - A Community Resource of Patient iPSC lines

In a bold effort to build on the AREDS2 investments, the NEI is working to:

  • correlate clinical AMD disease phenotypes in a cellular model with patient genotype and imaging information in the newly created AMD Integrative Biology Initiative,
  • make this Initiative available to the research community with induced pluripotent stem cells (iPSCs) derived from AREDS2 participants with specific genetic risk factors for AMD, and
  • cover a cohort of 73 AREDS2 patients (chosen based on known AMD risk alleles) in this undertaking that is done in partnership with the New York Stem Cell Foundation Research Institute (NYSCF).

There are over 50 iPSC lines now available from NYSCF and the accompanying genomic and phenotypic data will be available to the research community later this fall. 

Isogenic control lines in which the risk alleles have been corrected will be available next year. These iPSC lines are intended for research use and requestors will be required to submit a description of their research when requesting the lines.

How do I get these iPSC lines?  Contact NYSCF for the NEI Age-related Macular Degeneration Panel and include a brief statement of work on how you will use the lines. 

 

Image of Lamin Actin

NEI & NYSCF Collaboration

The NYSCF Research Institute and the NEI have generated iPSCs from AMD patients, which are available to the vision research community. See a complete list of the current iPSC lines.

Last updated: January 11, 2021